Faculty Collaboration Database

Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Health Psychol 1998 Jul;17(4):310-9

Date

08/11/1998

Pubmed ID

9697940

DOI

10.1037//0278-6133.17.4.310

Scopus ID

2-s2.0-0031820161 (requires institutional sign-in at Scopus site)   114 Citations

Abstract

Protease inhibitor combination therapies can reduce HIV viral load, improve immune system functioning, and decrease mortality from AIDS. These medical developments raise a host of critical new issues for behavioral research on HIV/AIDS. This article reviews developments in HIV combination therapy regimens and behavioral factors involved in these regimens and focuses on four key behavioral research areas: (a) the development of interventions to promote treatment adherence, (b) psychological coping with HIV/AIDS in the context of new treatments for the disease, (c) the possible influence of treatment on continued risk behavior, and (d) behavioral research in HIV prevention and care policy areas. Advances in HIV medical care have created important new opportunities for health psychologists to contribute to the well-being of persons with HIV/AIDS.

Author List

Kelly JA, Otto-Salaj LL, Sikkema KJ, Pinkerton SD, Bloom FR

Author

Jeffrey A. Kelly PhD Professor in the Psychiatry and Behavioral Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Acquired Immunodeficiency Syndrome
Anti-HIV Agents
Drug Therapy, Combination
HIV Infections
HIV Long-Term Survivors
HIV Protease Inhibitors
Health Behavior
Health Knowledge, Attitudes, Practice
Humans
Patient Care Team
Patient Compliance